Tech expert and USA Today nationally-syndicated tech-life columnist Jennifer Jolly joins TODAY to share a roundup of gadgets that will make life around the house simpler, safer and smarter. Items ...

Gilead Sciences (NASDAQ:GILD), a leading biopharmaceutical company, has today outlined plans to create $43 billion in value for the U.S. economy over the next five years through direct capital ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan, which ...

Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...

Over in Gilead, Nick visits the Guardian he shot as ... with Luke explaining that they’re picking up empty barrels from the kitchen. Thanks to the lockdown, the Guardian tells them to leave ...

Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New launches like Livdelzi provide growth opportunities but are unlikely to ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...

Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s Yuhan to help produce its HIV meds in a deal worth $80.9 million.

Gilead Sciences, a pharma company that dominates the market for HIV treatments, agreed in June to settle a case in federal court for $40 million that had been brought by 2,625 people living with HIV.

Cognizant has expanded its agreement with biopharmaceutical company Gilead Sciences to manage its global IT infrastructure, platforms and applications, and lead initiatives to accelerate its ...